Company Financials
Inozyme Pharma, Inc. Financials
United States dollar
business
Inozyme Pharma, Inc. Company Profile
Main Stock Listing
NASDAQ: INZY
Market Capitalization $258.2 Million as of July 1, 2025
Market Cap History
Valuations Metrics as of May. 5, 2024
| Trailing PE | |
| Forward PE | -2.96 |
| Price to Sales TTM | $ |
| Price to Book MRQ | $2.08 |
| Enterprise to Revenue | |
| Enterprise to EBITDA | -2.02 |
Financial Reports as of Dec. 31, 2023
Financials
| Fiscal Year Ends | 2023-12-31 |
| Most Recent Quarter | 2023-12-31 |
| Profit Margin | 0.00% |
| Operating Margin | 0.00% |
| Return on Assets TTM | -27.81% |
| Return on Equity TTM | -54.98% |
Income Statement
| Revenue TTM | $0 |
| Revenue per Share TTM | $ |
| Quarterly Revenue Growth | % |
| Gross Profit TTM | $0 |
| EBITDA | $-74,812,000 |
| Net Income to Common TTM | $-71,169,000 |
| Diluted EPS TTM | $-1.37 |
| Quarterly Earnings Growth YoY | % |
Balance Sheet
| Total Cash MRQ | $188,588,992 |
| Total Cash per Share MRQ | $3.05 |
| Total Debt MRQ | $ |
| Total Debt to Equity MRQ | 33.17 |
| Current Ratio MRQ | 13.36 |
| Book Value per Share MRQ | $2.27 |
Cash Flow
| Operating Cash Flow TTM | $-70,675,000 |
| Levered Free Cash Flow TTM | $-46,046,248 |
INZY Stock Info as of May. 5, 2024
Stock Statistics
| Shares Outstanding | 61,855,500 |
| Float Shares | 34,276,652 |
| Avg 10 Volume | 579,282 |
| Avg 30 Volume | None |
| Shares Short | 3,153,357 |
| Short Ratio | 3.24 |
| Short % of Shares | 5.14% |
| % Held by Insiders | 0.66% |
| % Held by Institutions | 92.92% |
Stock Price Summary
| Beta | 1.37 |
| Fifty Two Week Low | $2.69 |
| Fifty Two Week High | $7.80 |
| Fifty Two Week Change | -26.16% |
| Day 50 MA | $5.71 |
| Day 200 MA | $4.70 |
Dividends and Splits
| Forward Annual Dividend Rate | $ |
| Forward Annual Dividend Yield | % |
| Trailing Annual Dividend Rate | $0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Dividend Date | |
| Ex Dividend Date | |
| Last Split Factor | |
| Last Split Date |